1 | 12:30-12:45 | Lunch Symposium |
Clinical study on the efficacy and safety of supramolecular salicylic acid in the treatment of rosacea |
|
||||
2 | 12:45-13:00 | Lunch Symposium |
Clinical application of supramolecular salicylic acid in rosacea |
|
1 | 13:00-13:02 | Speech |
Report on Clinical Trails of Gold Multipolar RF Beauty Instrument and Thermage |
|
||||||||||
2 | 13:02-13:10 | Lunch Symposium |
Report on Clinical Trails of Gold Multipolar RF Beauty Instrument and Thermage |
|
||||||||||
3 | 13:10-13:28 | Discussion |
Household Anti-aging Technology Discussion |
|
||||||||||
4 | 13:28-13:30 | Summary |
Closing |
|
1 | 13:30-13:45 | Lunch Symposium |
The application value of TCS tapering strategy in the treatment of atopic dermatitis |
|
||||
2 | 13:45-14:00 | Lunch Symposium |
The Role of Propionibacterium Acnes and Inflammatory Responses in the Pathogenesis and Progression of Acne Vulgaris |
|
1 | 14:00-14:15 | Symposium |
Cutting edges in management of auto-immune related hair and scalp disorders |
|
||||
2 | 14:15-14:30 | Symposium |
The role of Th2 in early onset and persistence of alopecia areata |
|
||||
3 | 14:30-14:45 | Symposium |
Advances in humanized animal models for alopecia |
|
||||
4 | 14:45-15:00 | Symposium |
Induced pluripotent stem cell for hair transplant |
|
||||
5 | 15:00-15:15 | Symposium |
Real-life efficacy and safety of baricitinib in Chinese patients with severe alopecia areata: a single centre prospective study |
|
||||
6 | 15:15-15:30 | Symposium |
Skin organoid self-organization and hair regeneration |
|
1 | 16:00-16:20 | Symposium |
Managing refractory oral lesions in pemphigus |
|
||||
2 | 16:20-16:40 | Symposium |
Integrative single-cell analysis reveals distinct signatures of immune micro-environment and pathogenic antibody secreting cells in pemphigus cutaneous lesions |
|
||||
3 | 16:40-17:00 | Symposium |
Chronic localized blisters in pemphigus-It’s immunomechanism and therapeutic implication |
|
||||
4 | 17:00-17:20 | Symposium |
Proteses in pemphigoid diseases |
|
||||
5 | 17:20-17:30 | Discussion |
Q & A |